^
Association details:
| Biomarker: | TNFRSF8 positive |
|---|---|
| Cancer: | Cutaneous T-cell Lymphoma |
| Drug: | Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
10/25/2012
Excerpt:
Adcetris is indicated for the treatment of adult patients with CD30+ cutaneous T cell lymphoma (CTCL) after at least 1 prior systemic therapy.
Title:
Brentuximab vedotin (Adcetris®) is accepted for restricted use within NHSScotland.
Excerpt:
Brentuximab vedotin (Adcetris) is accepted for restricted use within NHSScotland...for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Source:
Title:
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Figure 2. Recommendations for the initial management of primary cutaneous CD30þ LPDs....Recent studies report high response rates of brentuximab vedotin (BV; an anti-CD30 monoclonal antibody coupled to the antitubulin agent monomethyl auristatin E) in patients with advanced MF/SS expressing CD30 [II, B].
DOI:
10.1093/annonc/mdy133
Source:
Title:
Imaging study with brentuximab in patients with lymphoma Beeldvormend onderzoek met brentuximab bij patiënten met lymfeklierkanker
Excerpt:
...• All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including:o Hodgkin lymphomao T-cell lymphomao Cutaneous T-cell lymphomao DLBCL• Age ≥18• Signed written informed consent form (approved by the Institutional Review Board [IRB]/ Independent Ethics Committee [IEC]) obtained prior to any study specific screening procedures• Measurable disease: on CT scan at least 1 lesion/node with a long axis of > 1.5 cm and at least one positive lesion on 18F-FDG PET scan u2028• WHO performance status 0-2 (see appendix A) u2028• Adequate hepatic function: total bilirubin ≤ 1.5 times ULN (unless due to lymphoma involvement of the liver or a known history of Gilbert's syndrome as defined by > 80% unconjugated bilirubin) and ALAT/ASAT ≤ 3 times ULN (unless due to lymphoma involvement of the liver; in that case ALAT/ASAT may be elevated up to 5 times ULN)• Adequate renal function: GFR > 50 ml/min as estimated by the Cockroft&Gault formula at rehydration: CrCL = (140-age [in years] x weight [kg] (x 0.85 for females) (0.815 x serum creatinine [μmol/L]) u2028• Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L and platelet count ≥100 x 109/L, unless caused by diffuse bone marrow infiltration by lymphoma• Hemoglobin must be ≥ 8 g/dL (5.0 mmol/L), transfusion is allowed u2028• Life expectancy of >3 months with treatment u2028• Negative pregnancy test at study entry, if applicable • Alle patiënten met histologisch bewezen CD30-positieve (d.w.z. ...
Trial ID:
Source:
Title:
A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
Excerpt:
...Histologically confirmed cHL, CTCL (MF and pcALCL) or sALCL with CD30 positive....
Trial ID:
More C2 evidence
Source:
Title:
A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
Excerpt:
...Histologically- confirmed cluster of differentiation antigen 30 positive (CD30+) disease by local laboratory assessment and pathology review....
Trial ID:
Source:
Title:
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Excerpt:
...Maximum tolerated dose, dose-limiting toxicities of the combination therapy, and recommended phase 2 dose, in patients with relapsed/refractory cutaneous T-cell lymphoma, CD30-positive Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma. ...
Trial ID:
Source:
Title:
TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome
Excerpt:
...- Histologically confirmed CD30-positive (defined in this study as ≥ 1% expression) Mycosis Fungoides (including large cell transformation variant) or...
Trial ID:
Source:
Title:
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
Excerpt:
...- CD30-positivity by immunohistochemistry of >= 1%...
Trial ID:
Source:
Title:
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Excerpt:
...Patients' biopsies must be histologically confirmed CD30 positive within 36 months of enrollment....
Trial ID:
Source:
Title:
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Excerpt:
...- CD30 staining is to be performed on fresh biopsy or archival formalin-fixed paraffin-embedded (FFPE) tissue however CD30 positivity is...
Trial ID:
Less C2 evidence
Source:
Title:
Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas
Published date:
05/31/2023
Excerpt:
Our objective was to assess the effectiveness of BV + CHP in aggressive CD30+CTCL….After a median [IQR] follow-up of 17.2 [13.2-21.0] months, 6/7 patients achieved an ORR lasting ≥4 months. The median [IQR] duration of response was 9.5 [5.9-11.1] months and the median [IQR] progression free survival was 14.9 [11.6-16.4] months.
Secondary therapy:
doxorubicin hydrochloride + cyclophosphamide + prednisolone
DOI:
10.1080/10428194.2023.2216820
Source:
Title:
Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma
Published date:
02/22/2021
Excerpt:
...patients with CD30-positive cutaneous T-cell lymphoma treated with BV...Brentuximab vedotin (BV)...Complete remission (CR) was reached in 30.8 % of the patients, and the objective response rate (ORR) was 84.6 %.
DOI:
10.1111/ddg.14342
Source:
Title:
Face and Neck Cutaneous T‑Cell Lymphomatoid Papulosis: Case Report
Published date:
09/01/2023
Excerpt:
An 82-year-old female patient presented with lesions involving face and neck...With these findings, the diagnosis of primary cutaneous CD30+ lymphoproliferative disease, lymphomatoid papulosis type was made. We treated the patient with 3 courses of systemic B+CHP (brentuximab 1.8 mg/kg, cyclophosphamide 750 mg/m2, doxorubicin 25 mg/m2, prednisolone 100 mg, 5 days). No side effects were observed. After 3 courses of treatment, the lesions regressed almost completely.
Secondary therapy:
CHP
Source:
Title:
PRIMARY CUTANEOUS GAMMA-DELTA T-CELL LYMPHOMA: SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN ASSOCIATED WITH CHEMOTHERAPY AS BRIDGING THERAPY TO HAPLOIDENTICAL TRANSPLANT
Published date:
06/12/2020
Excerpt:
...the tumor was CD30 positive, we decided to add Bv to Etoposide, Citarabine and Cisplatin (Br-ESHAP)...He received three cycles of Br-ESHAP developing a clinical and metabolic CR. On November 2019 he received a haploidentical HSCT from his sister,... No skin progression or extracutaneous involvement has been observed 3 months after the haploidentical HSCT.
